Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Elevated Bilirubin at Baseline in the Phase 3 Placebo-Controlled RESPONSE Trial

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Elevated Bilirubin at Baseline in the Phase 3 Placebo-Controlled RESPONSE Trial

	AASLD 2025 Nov 7-11 Wash DC Sonal Kumar1